PHASE II EVALUATION OF 3-DAY TOPOTECAN WITH CYCLOPHOSPHAMIDE IN THE TREATMENT OF RECURRENT OVARIAN CANCER

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

HANJANI P.; NOLTE S.; SHAHIN M.S.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Obstetrics, Gynecology and Infertility Year:2001 | Volume:3 | Issue:5-6 Page(s): 1-4

Download Full-Text

View:

259

Download:

Cites:

Information Journal Paper

Title

PHASE II EVALUATION OF 3-DAY TOPOTECAN WITH CYCLOPHOSPHAMIDE IN THE TREATMENT OF RECURRENT OVARIAN CANCER

Author(s)

HANJANI P. | NOLTE S. | SHAHIN M.S. | Issue Writer Certificate

Keywords

Not Registered.

Abstract

Objective: The aim of this trial was to investigate the toxicity and efficacy of a 3-day topotecan administration schedule in combination with cyclophosphamide in the management of recurrent ovarian cancer. Methods: Patients with recurrent measurable ovarian cancer who had up to 2 prior chemotherapy regimens for the management of their disease participating in this phase II trial were to receive topotecan at a dose of 1.25 mg/m2/day x 3 days in combination with cyclophosphamide at 600 mg/m2 on day 1 every 21 days. Dose escalation and reductions were permitted.Results: A total of 36 patients (median age = 65; range 37-84) were treated with this combination regimen. 17 were platinum sensitive and 19 were platinum resistant. A total of 169 cycles of chemotherapy was administered (Median = 4; range = 1-10). Major toxicity included grade 4 neutropenia (68.6%), peutropenic fever (7.1%), grade 3 thrombocytopenia (18.3%), and requirement for blood transfusion (19.5%). Dose escalation was possible in 3 (8.3%), and dose reduction was required in 14 (38.9%) patients. Overall response rate was 25% and 44.5% demonstrated stable disease. Median progression free interval and overall survival was 5:4 and 23.5 months respectively, independent of platinum sensitivity. Conclusion: The 3-day topotecan schedule in combination with cyclophosphamide appears to have good activity in recurrent ovarian cancer regardless of platinum sensitivity. Neutropenia was the only severe toxicity and was less prevalent than other reported trials of topotecan. This tolerable regimen offers patients more convenience and appears to have moderate activity.

Cites

No record.

References

No record.

Cite

APA: Copy

HANJANI, P., NOLTE, S., & SHAHIN, M.S.. (2001). PHASE II EVALUATION OF 3-DAY TOPOTECAN WITH CYCLOPHOSPHAMIDE IN THE TREATMENT OF RECURRENT OVARIAN CANCER. IRANIAN JOURNAL OF OBSTETRICS, GYNECOLOGY AND INFERTILITY, 3(5-6), 1-4. SID. https://sid.ir/paper/551078/en

Vancouver: Copy

HANJANI P., NOLTE S., SHAHIN M.S.. PHASE II EVALUATION OF 3-DAY TOPOTECAN WITH CYCLOPHOSPHAMIDE IN THE TREATMENT OF RECURRENT OVARIAN CANCER. IRANIAN JOURNAL OF OBSTETRICS, GYNECOLOGY AND INFERTILITY[Internet]. 2001;3(5-6):1-4. Available from: https://sid.ir/paper/551078/en

IEEE: Copy

P. HANJANI, S. NOLTE, and M.S. SHAHIN, “PHASE II EVALUATION OF 3-DAY TOPOTECAN WITH CYCLOPHOSPHAMIDE IN THE TREATMENT OF RECURRENT OVARIAN CANCER,” IRANIAN JOURNAL OF OBSTETRICS, GYNECOLOGY AND INFERTILITY, vol. 3, no. 5-6, pp. 1–4, 2001, [Online]. Available: https://sid.ir/paper/551078/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops